MERCK CO. DL-01/ US58933Y1055 /
08/08/2024 07:57:05 | Chg. 0.0000 | Volume | Bid21:59:50 | Ask21:59:50 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
102.4000EUR | 0.00% | - Turnover: - |
104.2000Bid Size: 150 | 104.4000Ask Size: 150 | 264.24 bill.EUR | - | - |
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
25/01
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
12/12/2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA